ocugen annual report

Results of Operations Comparison of the Years Ended December 31, 2019 and 2018 The following table summarizes the results of our operations for the years ended December 31, 2019 and 2018 (in thousands): Research and development expense Research and development expense decreased by $2.2 million for the year ended December 31, 2019 when compared to the year ended December 31, 2018 primarily as a result of a net decrease in program development and clinical trial activities of $1.8 million and a net decrease of $0.4 million in other costs. Find the latest Ocugen, Inc. (OCGN) stock quote, history, news and other vital information to help you with your stock trading and investing. … August 14, 2020. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements (S-1, S-8) and prospectus (FWP). Announces Closing of $23 Million Registered Direct Offering of Common Stock. Voting on Items 1, 3, 4, 5 and 6 will be open until the adjournment of Ocugen's 2020 Annual Meeting of Stockholders on December 23, 2020. Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2020 OCUGEN, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36751 04-3522315 (State or Other Jurisdiction of. PRESS RELEASE GlobeNewswire. Ocugen, Inc. 0001628280-21-002739.pdf. MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at the H.C. Wainwright Global Life Sciences Conference being held on March 9-10, the 33 rd Annual … 0001628280-21-002739.rtf. Malvern, PA 19355. Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news. Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. It is understandable that investor optimism is growing ahead of the company’s current quarter results. While our significant accounting policies are described in more detail in the notes to the consolidated financial statements appearing elsewhere in this report, we believe that the following accounting policies and estimates are those most critical to the preparation of our consolidated financial statements: Stock-based compensation We account for our stock-based compensation awards in accordance with the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation-Stock Compensation ("ASC 718"). Announces Closing of $23 Million Registered Direct Offering of Common Stock. Ocugen, Inc. has reached its limit for free report views. Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81% … Upgrade your company profile to unlock all of your annual report content on AnnualReports.com. If you hold your shares of our common stock with a broker, bank or other holder of record as nominee or agent, you may be subject to an earlier voting deadline and you should … Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81% [March 03, 2021] Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing COVID-19 in those without … File Number) (I.R.S. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. Ocugen, Inc., which has a market valuation of $1.67 Billion, is expected to release its quarterly earnings report Mar 25, 2021- Mar 29, 2021. MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to … February 2, 2021. This page shows recent SEC filings related to Ocugen, Inc. Voting on Item 2 will be open until the conclusion of the Annual Meeting on January 13, 2021. Voting on Item 2 … Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Ocugen, … Feb. 11, 2021, … Annual Filings. Company. MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at the H.C. Wainwright Global Life Sciences Conference being held on March 9-10, the 33 rd Annual … The Annual Meeting will resume with respect to Item 2 at 11:00 a.m. Eastern time on January 13, 2021 and will continue to be held virtually. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and … Additionally, prior to the resumption of the Annual Meeting, Ocugen intends to amend its Definitive Proxy Statement to restate Item 2. Annual report which provides a comprehensive overview of the company for the past year. Create an account, Condensed Consolidated Balance Sheets (Parenthetical), Condensed Consolidated Statements Of Operations And Comprehensive Loss, Condensed Consolidated Statements Of Stockholders' Equity (Deficit), Condensed Consolidated Statements Of Stockholders' Equity (Parenthetical), Condensed Consolidated Statements Of Cash Flows, Summary Of Significant Accounting Policies, Summary Of Significant Accounting Policies (Policies), Summary Of Significant Accounting Policies (Tables), Net Loss Per Share Of Common Stock (Tables), Nature Of Business - Reverse Stock Split (Details), Nature Of Business - Going Concern (Details), Summary Of Significant Accounting Policies (Narrative) (Details), Summary Of Significant Accounting Policies (Summary Cash, Cash Equivalents And Restricted Cash) (Details), Merger And Financing - Pre-Merger Financing (Details), Merger And Financing - Merger With Histogenics (Details), Net Loss Per Share Of Common Stock (Details), License And Collaboration Agreements (Details), Debt - Schedule Of Fair Value Of The Embedded Features (Details), Debt - Convertible Notes Other Information (Details), Debt - Senior Secured Convertible Notes (Details), Stock-Based Compensation - Schedule Of Compensation Expense For Options Granted (Details), Stock-Based Compensation - Schedule Of Valuation Assumptions (Details), Stock-Based Compensation - Schedule Options To Purchase Common Stock (Details), Commitments - Operating Leases, Components Of Lease Expense (Details), Commitments - Operating Leases, Supplemental Balance Sheet Information (Details), Commitments - Operating Leases, Supplemental Information Related To Leases (Details), Commitments - Operating Leases, Future Minimum Lease Payments (Details), Commitments - Finance Leases, Future Minimum Lease Payments (Details), Schedule Of Activity Of The Pre-Merger Financing Warrants (Details), Schedule Of Roll-Forward Of Series? Annual Reports. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. To determine whether a contract is considered indexed to the issuer's own equity, we perform the following two-step analysis: (1) evaluate whether the contract contains any exercise contingencies and, if so, whether they disqualify the contract from being classified as equity, and (2) assess whether the settlement terms are consistent with equity classification. Get the detailed quarterly/annual income statement for Ocugen, Inc. (OCGN). Find out the revenue, expenses and profit or loss over the last fiscal year. The gross proceeds of the offering are expected to be approximately $23 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006. Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ocugen, Inc.. Ocugen Inc. Ocugen, Inc. The H.C. Wainwright 22 nd Annual Global Investment Conference will take place on September 14-16 virtually.. About Ocugen, Inc. Ocugen, Inc. is a … Ocugen partnered on development of a Covid-19 vaccine. January 8, 2021. • The Company had 52,625,228 shares of common stock outstanding as of December 31, 2019. Ocugen Inc Second Quarter 2020 Financial Results and Recent Business Highlights. Please wait while we load the requested 10-K report or click the link below: https://last10k.com/sec-filings/report/1372299/000162828020004221/ocgn-20191231.htm. Dec 31, 2018. The $0.4 million net decrease in other research and development costs is primarily related to (a) a $0.2 million decrease in employee-related expenses due to a decrease in headcount and (b) a $0.2 million decrease in license fees associated with a license milestone achieved during 2018. Click here for webcast. Filing Group. Form Description. MALVERN, Pa., Feb. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate … Document Date. • Ocugen reported a net loss of $20.2 million, or $1.46 loss per share, for the year ended December 31, 2019, compared to a net loss of $18.2 million, or $3.67 loss per share, for the year ended December 31, 2018. Mar 22, 2019. Voting on Items 1, 3, 4, 5 and 6 will be open until the adjournment of Ocugen's 2020 Annual Meeting of Stockholders on December 23, 2020. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021. Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 sharesMALVERN, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, …

Mastercard Interchange Rates 2021, Fluentd Timestamp 1970, I Comme Icare Film Complet, Zaza Cars Indirizzo, Wood Exterior Shutters, Grenadian Revolution Summary, How To Write Rules For A Game, National Youth Tobacco Survey 2019, Japanese Vape Juice, Lumina Homes Bacolod East, Places To Eat Dublin,